Literature DB >> 22204827

Type I interferons directly down-regulate BCL-6 in primary and transformed germinal center B cells: differential regulation in B cell lines derived from endemic or sporadic Burkitt's lymphoma.

Daniel Salamon1, Monika Adori, Minghui He, Peter Bönelt, Eva Severinson, Lorand L Kis, Liang Wu, Dorina Ujvari, Benjamin Leveau, Noemi Nagy, George Klein, Eva Klein.   

Abstract

Type I interferons (IFN) exert multiple effects on both the innate and adaptive immune system in addition to their antiviral and antiproliferative activities. Little is known, however about the direct effects of type I IFNs on germinal center (GC) B cells, the central components of adaptive B cell responses. We used Burkitt's lymphoma (BL) lines, as a model system of normal human GC B cells, to examine the effect of type I IFNs on the expression of BCL-6, the major regulator of the GC reaction. We show that type I IFNs, but not IFNγ, IL-2 and TNFα rapidly down-regulate BCL-6 protein and mRNA expression, in cell lines derived from endemic, but not from sporadic BL. IFNα-induced down-regulation is specific for BCL-6, independent of Epstein-Barr virus and is not accompanied by IRF-4 up-regulation. IFNα-induced BCL-6 mRNA down-regulation does not require de novo protein synthesis and is specifically inhibited by piceatannol. The proteasome inhibitor MG132 non-specifically prevents, while inhibitors of alternate type I IFN signaling pathways do not inhibit IFNα-induced BCL-6 protein downregulation. We validate our results with showing that IFNα rapidly down-regulates BCL-6 mRNA in purified mouse normal GC B cells. Our results identify type I IFNs as the first group of cytokines that can down-regulate BCL-6 expression directly in GC B cells.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22204827     DOI: 10.1016/j.cyto.2011.12.001

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  5 in total

1.  Latency type-dependent modulation of Epstein-Barr virus-encoded latent membrane protein 1 expression by type I interferons in B cells.

Authors:  Daniel Salamon; Monika Adori; Dorina Ujvari; Liang Wu; Lorand L Kis; Harsha S Madapura; Noemi Nagy; George Klein; Eva Klein
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

Review 2.  New effector functions and regulatory mechanisms of BCL6 in normal and malignant lymphocytes.

Authors:  Karen L Bunting; Ari M Melnick
Journal:  Curr Opin Immunol       Date:  2013-05-30       Impact factor: 7.486

3.  Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy.

Authors:  Gabriel G Vega; Luz Areli Franco-Cea; Sara Huerta-Yepez; Héctor Mayani; Sherie L Morrison; Benjamin Bonavida; Mario I Vega
Journal:  Int J Oncol       Date:  2015-09-16       Impact factor: 5.650

4.  Identification of new type I interferon-stimulated genes and investigation of their involvement in IFN-β activation.

Authors:  Xiaolin Zhang; Wei Yang; Xinlu Wang; Xuyuan Zhang; Huabin Tian; Hongyu Deng; Liguo Zhang; Guangxia Gao
Journal:  Protein Cell       Date:  2018-02-09       Impact factor: 14.870

5.  Chronic simian immunodeficiency virus infection is associated with contrasting phenotypes of dysfunctional Bcl6+ germinal center B cells or Bcl6- Bcl2+ non-germinal center B cells.

Authors:  Olusegun O Onabajo; Mark G Lewis; Joseph J Mattapallil
Journal:  J Cell Mol Med       Date:  2018-09-06       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.